Compare GE HealthCare Technologies Inc. Common Stock (GEHC) vs Procter & Gamble Co (PG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE HealthCare Technologies Inc. Common Stock vs Procter & Gamble Co — how do they compare? GE HealthCare Technologies Inc. Common Stock trades at $68.66 (market cap $31.07B), while Procter & Gamble Co trades at $157.37 (market cap $355.46B). The key difference: Procter & Gamble Co is far larger — about 11.4× GE HealthCare Technologies Inc. Common Stock's market cap, and Procter & Gamble Co pays the higher dividend (2.85%). Which is the better fit depends on your goals.
| GEHC | PG | |
|---|---|---|
Market Cap | $31.07B | $355.46B |
Volume | 3,443,020 | 5,731,171 |
Sector | Health | Consumer Staples |
52-Week High | $88.16 | $167.18 |
52-Week Low | $59.48 | $138.10 |
Enterprise Value | $39.53B | $381.30B |
Dividend Yield | 0.23% | 2.85% |
Typical Hold Time | — | 132 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
Procter & Gamble (PG) trades at $156.57, up 2.2% today, near its consensus price target of $160.13. The stock shows bullish technical signals with strong moving average support and has beaten earnings estimates for three consecutive quarters. Revenue reached $84.28B in 2025 with a net income margin of 18.44%, while the company maintains a robust dividend history and positive cash flow trends.
PG offers stable growth with high profitability and shareholder returns, but premium valuation multiples pose near-term upside limitations. Risks include soft demand outlook and competitive pressures, though analyst consensus remains bullish with 53% buy ratings. The stock's resilience in volatile markets supports its appeal for dividend-focused investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
